Can Personalized Medicine and Comparative Effectiveness Coexist? The Experts Weigh In
This article was originally published in RPM Report
Executive Summary
Government, academic and industry experts comment on the potential for personalized medicine and comparative effectiveness research to support each other--and the consequences if they don't.
You may also be interested in...
Best of the Blog: Personalized Medicine vs. Comparative Effectiveness
Readers of The IN VIVO Blog and The RPM Report's First Take responded to a post on whether proponents of personalized medicine can also be supporters of comparative effectiveness research. We asked readers to weigh in on that question. Their emails initiated a lively discussion on the future of health care so we've picked excerpts from the most noteworthy responses to share.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.